

**INTENDED USE**

The SPIFE Nexus ImmunoFix method is a fully automated solution intended for the qualitative identification of monoclonal gammopathies in serum and urine using protein electrophoresis and immunofixation on the SPIFE Nexus system.

For *In Vitro* Diagnostic Use.

RX Only

**SUMMARY**

Immunofixation electrophoresis (IFE) has been used for the study of immunoglobulins since 1976.<sup>1,2</sup> It is a two-stage procedure using agarose gel high resolution electrophoresis in the first stage and immunoprecipitation in the second. There are numerous applications for IFE in research, forensic medicine, genetic studies and clinical laboratory procedures. The greatest demand for IFE is in the clinical laboratory where it is primarily used for the detection of monoclonal gammopathies. A monoclonal gammopathy is a primary disease state in which a single clone of plasma cells produces elevated levels of an immunoglobulin of a single class and type. Such immunoglobulins are referred to as monoclonal proteins, M-proteins or paraproteins. Their presence may be of a benign nature or of uncertain significance. In some cases, they are indicative of a malignancy such as multiple myeloma or Waldenstrom's macroglobulinemia. Differentiation must be made between polyclonal and monoclonal gammopathies because polyclonal gammopathies are only a secondary disease state due to clinical disorders such as chronic liver diseases, collagen disorders, rheumatoid arthritis and chronic infections. The SPIFE Nexus IFE method offers many advantages including hands-free operation, ease of interpretation, excellent resolution, reagent conservation and rapid turnaround.

**PRINCIPLE**

Proteins are first resolved by electrophoresis. In the second stage, the soluble antigen and antibody are allowed to react. The resultant antigen-antibody complex(es) may become insoluble (as long as the antibody is in slight excess or near equivalency) and precipitate. The precipitation rate depends on the proportions of the reactants, temperature, salt concentration and the pH of the solution. The unreacted proteins are removed by a washing step and the antigen-antibody complex (which might be visible as a white cloudy band in the unstained gel against a dark background) is visualized by staining. The bands in the protein separation are compared with the precipitin bands obtained with immunofixation.

**REAGENTS****1. SPIFE IFE-15 Gel**

**Ingredients:** Each gel contains agarose in tris-barbital/MOPS buffer with a stabilizer and a preservative.

**WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY. CAUTION: DO NOT INGEST.** The gel contains barbital which, in sufficient quantity, can be toxic.

**Preparation for Use:** The gels are ready for use as packaged.

**Storage and Stability:** The gels should be stored horizontally at room temperature (15 to 30°C) and are stable until the expiration date indicated on the package. The gels must be stored in the protective packaging in which they are shipped. **DO NOT REFRIGERATE OR FREEZE.**

**Signs of Deterioration:** Any of the following conditions may indicate deterioration of the gel: (1) crystalline appearance indicating the agarose has been frozen, (2) cracking and peeling indicating drying of the agarose, (3) bacterial growth indicating contamination, (4) thinning of gel blocks.

**2. SPIFE Nexus Violet**

**Ingredients:** The stain is comprised of 0.5% (w/v) acid violet stain and 10% acetic acid.

**WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY. DO NOT INGEST.**

**Preparation for Use:** The stain is ready for use as packaged.

**Storage and Stability:** The stain solution is stable for one year when stored at 15 to 30°C in a closed container.

**Signs of Deterioration:** The stain should be a homogeneous mixture free of precipitate.

**3. Citric Acid Destain**

**Ingredients:** After dissolution, the destain contains 0.3% (w/v) citric acid.

**WARNING: FOR IN-VITRO DIAGNOSTIC USE. DO NOT INGEST—IRRITANT.**

**Preparation for Use:** Pour 11 L of deionized water into the Destain vat. Add the entire package of destain and mix until completely dissolved.

**Storage and Stability:** Store the destain at 15 to 30°C. It is stable until the expiration date on the package.

**Signs of Deterioration:** Discard if solution becomes cloudy.

**4. Clear Wash**

**Ingredients:** The powder contains anionic and nonionic surfactants, sodium carbonate, enzymes and sodium chloride.

**WARNING: FOR IN-VITRO DIAGNOSTIC USE**

**Preparation for Use:** Dissolve the powder in 8 L of deionized water and mix thoroughly.

**Storage and Stability:** Store the dry powder at 15 to 30°C until the expiration date indicated on the label. The buffer solution should be stored at 15 to 30°C.

**Signs of Deterioration:** The buffer solution should be discarded if it shows signs of bacterial contamination.

**5. SPIFE Nexus Pipette Wash**

**Ingredients:** The buffer solution contains a sodium hydroxide solution.

**WARNING: FOR IN-VITRO DIAGNOSTIC USE. DANGER: CORROSIVE—NEVER PIPETTE BY MOUTH. DO NOT INGEST.**

**Preparation for Use:** The buffer solution is ready for use as packaged.

**Storage and Stability:** The buffer solution should be stored at 15 to 30°C and is stable until the expiration date indicated on the vial.

**Signs of Deterioration:** The buffer solution should be a clear solution.

**6. SPIFE Nexus IFE Protein Fixative**

**Ingredients:** The fixative contains 4.0% sulfosalicylic acid, 6.7% trichloroacetic acid, 0.2% glutaraldehyde and 1.7% guanidine HCl.

**WARNING: FOR IN-VITRO DIAGNOSTIC USE. DANGER: CORROSIVE—NEVER PIPETTE BY MOUTH. DO NOT INGEST.**

**Preparation for Use:** The fixative is ready for use as packaged.

**Storage and Stability:** The fixative should be stored at 2 to 8°C and is stable until the expiration date indicated on the vial.

**Signs of Deterioration:** The fixative should be a clear solution.

**7. Antisera to Human IgG, IgA, IgM, Kappa Light Chain and Lambda Light Chain**

**Ingredients:** Antisera vials in the kit contain monospecific antisera to human immunoglobulin heavy chains, IgG, IgM, IgA and to human light chains, Kappa and Lambda. The antisera have been prepared in goat. Each vial of antiserum contains a stabilizer and sodium azide as a preservative.

**WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY.** To prevent the formation of toxic vapors, do not mix with acidic solutions. When discarding, always flush sink with copious amounts of water. This will prevent the formation of metallic azides which, when highly concentrated in metal plumbing, are potentially explosive. In addition to purging pipes with water, plumbing should occasionally be decontaminated with 10% NaOH.

**Preparation for Use:** The antisera are ready for use as packaged.

**Storage and Stability:** The antisera should be stored at 2 to 8°C and are stable until the expiration date indicated on the vial.

**Signs of Deterioration:** Extremely cloudy antisera may be indicative of bacterial contamination.

## INSTRUMENT

A SPIFE Nexus analyzer must be used to apply samples, electrophorese, apply antisera and fixative, wash, stain, destain, dry and then scan the gel. The gels may also be scanned on a separate densitometer such as the QuickScan Touch Plus (Cat. No. 1640). Refer to the Operator's Manual for detailed instructions.

## SPECIMEN COLLECTION AND HANDLING

**Specimen:** Fresh serum or urine is the specimen of choice.

**Storage and Stability:** If storage is necessary, store serum samples covered at 2 to 8°C for 2 weeks. Urine samples may be stored covered at 2 to 8°C for up to 9 days. Samples should be discarded if there are signs of contamination, marked turbidity or gross hemolysis. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine specific stability criteria for its laboratory.

### Interfering Factors:

1. Evaporation of uncovered specimens may cause inaccurate results.
2. Use of plasma will cause a fibrinogen band to appear as a distinct narrow band between the beta and gamma fractions. Although fibrinogen does not react with the antisera provided in the kit, fibrinogen may potentially adhere to the gel matrix resulting in nonspecific banding patterns.

## PROCEDURE

**Materials provided:** The following materials needed for the procedure are contained in the SPIFE Nexus IFE-15 Kit. Individual items are not available.

|                                               |          |        |
|-----------------------------------------------|----------|--------|
| SPIFE IFE-15 Gels (10)                        | Fixative | 1 vial |
| SPIFE Nexus Violet (1 vial)                   | IgG      | 1 vial |
| Clear Wash (1 pkg)                            | IgA      | 1 vial |
| Citric Acid Destain (1 pkg)                   | IgM      | 1 vial |
| SPIFE Blotter C (10)                          | Kappa    | 1 vial |
| SPIFE Nexus Blotter D (10)                    | Lambda   | 1 vial |
| SPIFE Nexus Pipette Wash (1 Vial)             |          |        |
| Serrated Blade Applicator Kit, 18 Sample (50) |          |        |

**Materials provided by Helena Laboratories but not contained in the kit:**

| Item                                          | Cat. No. |
|-----------------------------------------------|----------|
| SPIFE Nexus Analyzer                          | 1650     |
| QuickScan Touch Plus                          | 1640     |
| SPIFE Nexus Reagent Applique Set (3 pack)     | 2588     |
| SPIFE IFE-15 Dispo Cup Tray                   | 3362     |
| SPIFE IFE-9/15 Dispo Sample Cups              | 3363     |
| SPIFE Gel Block Remover                       | 1115     |
| SPIFE Nexus Cassettes                         | 2580     |
| SPIFE Nexus Applicator Template               | 2570     |
| SPIFE Nexus Applicator Blade Weights          | 2572     |
| SPIFE Nexus Dispo Stain Cups                  | 2575     |
| Pos ID Labels for Touch & SPIFE Nexus Systems | 1696     |
| REP Prep                                      | 3100     |
| SPIFE Nexus Reagent Roller                    | 2583     |
| SPIFE Nexus Ready Run Kit                     | 2582     |
| SPIFE Nexus Antisera Spreader Tips            | 2574     |
| SPIFE Nexus Carbon Electrode Insert           | 2576     |

|                                        |      |
|----------------------------------------|------|
| SPIFE Nexus A22 Short Electrode Insert | 2577 |
| SPIFE Nexus Flat Electrode Insert      | 2589 |
| SPIFE Nexus Fixative                   | 2413 |
| IFE Antisera to Kappa                  | 9425 |
| IFE Antisera to Lambda                 | 9426 |
| IFE Antisera to IgD                    | 9419 |
| IFE Antisera to IgE                    | 9420 |
| IFE Antisera to Free Kappa             | 9422 |
| IFE Antisera to Free Lambda            | 9423 |
| ImmunoFix Controls                     | 9400 |

## Materials and Supplies Needed but not Supplied:

0.85% saline

## STEP-BY-STEP METHOD

### I. Sample Preparation

Desired dilutions are operator programmable and may be individually set. Available dilutions are Neat; 1 in 2; 1 in 3; 1 in 4; 1 in 5; 1 in 6; 1 in 7; 1 in 8; 1 in 10; 1 in 12; 1 in 14; 1 in 16; 1 in 18, and 1 in 20 with options ranging from Neat to 1:20. Dilutions are automatically pipetted into the sample cups at a volume of 19 µL per well. See the SPIFE Nexus Operator's Manual for additional instructions. More concentrated samples are more likely to prozone while the more dilute samples may not exhibit desired sensitivity.

#### Serum

The SPIFE Nexus automatically samples and dilutes the specimens. By default, the patient serum samples are diluted 1:3 (1 part serum with 2 parts 0.85% saline) for serum protein and λ lanes, diluted 1:5 (1 part serum with 4 parts 0.85% saline) for IgA and IgM lanes, and diluted 1:8 (1 part serum with 7 parts 0.85% saline) for IgG and K lanes. However, due to desired sensitivity variations, serum samples may also be diluted as follows:

|     |                     |
|-----|---------------------|
| IgG | = 1:5 to 1:10       |
| IgA | = undiluted to 1:5  |
| IgM | = undiluted to 1:5  |
| κ   | = undiluted to 1:10 |
| λ   | = undiluted to 1:5  |

#### Urine

Due to differences in the running parameters, urine specimens cannot be processed on the SPIFE Nexus in combination with serum samples unless urine specimens are applied using template application. The ImmunoFixation procedure in combination with template urine application is available on the Helena website (<https://www.helena.com/procedures.htm>).

Urine samples should be concentrated if a higher sensitivity is desired. A total protein range of 500-3,000 mg/dL is generally sufficient for optimum sensitivity. The sensitivity is approximately 1 mg/dL for a single band. Shake samples to homogenize. Centrifuge desired volume at 2000 x g for 5 minutes. Remove supernatant and concentrate to lab specifications per laboratory protocol.

The SPIFE Nexus automatically samples and dilutes the specimens as follows:

|     |        |
|-----|--------|
| SP  | = Neat |
| IgG | = Neat |
| IgA | = Neat |
| IgM | = Neat |
| κ   | = Neat |
| λ   | = Neat |

For urine specimen volumes measuring less than 500 µL contact Technical Services for instructions on manual loading.

### II. SPIFE Nexus Preparation

- A. Fill the designated bottles with 0.85% saline, deionized water, destain and Clear Wash Solution.
- B. Turn on the SPIFE Nexus. Click on the SPIFE Nexus icon to initialize it.

- C. If this is the first test of the day, prime the instrument according to the instructions in the SPIFE Nexus Operator's Manual.
- D. Load the correct number of uncapped patient sample test tubes into test tube racks and place racks within the tube transport area.
- E. Open the main door of the instrument and prepare the items onboard the instrument.
  1. Ensure that each of the following items are in their respective onboard storage locations: **Platen Cover** with the Electrode Insert, **Antisera Spreader Tip**, and **Dryer Cover** with the red sticker toward the back of the instrument.
- 2. Onboard Reagent Chiller**
  - a. Uncap and place the Antisera and Protein Fixative into the labeled onboard Reagent Chiller positions.
  - b. Uncap and place the Saline Diluent into Diluent Well 1, and Pipette Wash into Diluent Well 2 of the Reagent Chiller.
- 3. Sample Cup Tray**
  - a. Prepare the sample cup tray with the appropriate Disposable Sample Cups. Slide the sample cups into the cup tray.
  - b. Place the cup tray onto the sample tray platform.
- 4. Stain/Reagent Dispenser**
  - a. Fill two Stain Cups each with 400 µL of SPIFE Nexus Violet stain. Place the Stain Cups in the outer two slots of the Stain/Reagent Dispenser. **NOTE: Do not add stain to the middle slot.**
  - b. Place a clean Reagent Roller bar between the hooks on the Stain/Reagent Dispenser.
- 5. Consumables Tray**
  - a. Slide the Consumables Tray forward from its home position.
  - b. Prepare the Applicator Holder
    - (1) Place an IFE-15 Applicator Template (Applicator Blade Template 4) on top of the Applicator Holder. Place Applicator Blades in the designated slots corresponding to the sample cups loaded within the sample tray. **NOTE: The Applicator Blades will only fit into the slots in the Applicator Holder one way; do not try to force the Applicator Blades into the slots.**
    - (2) Place the Applicator Blade Weights on top of the Applicator Blades with the thick side facing the front of the instrument.
  - c. Prepare the Blotter Holder
    - (1) Flip the Blotter Holder upside down so the foam surface is upright and place the Blotter Guide around the foam to assist in blotter placement. Locate the double-sided tape on the SPIFE Nexus Blotter D and remove the adhesive backing. Adhere the blotter to the foam surface of the Blotter Holder. Remove the Blotter Guide and place the Blotter Holder back in the designated location within the Consumables Tray with the green dot facing toward the front of the instrument.
  - d. Slide the Consumables Tray into position in the back of the instrument. **Note: Do not store extra components or consumables in the Consumables Tray during a test.**
- 6. Gel Cassette**
  - a. Place the bottom half of the Gel Cassette on the electrophoresis platen with the two pins lined up on the left side.
  - b. Dispense 2 mL of REP Prep on the platen.
  - c. Remove the gel from the protective packaging and discard the overlay.
  - d. Using a SPIFE Blotter C, gently blot the entire gel. Discard the blotter.
  - e. Place the left edge of the gel into the bottom of the cassette fitting the round hole over the upper pin and the obround hole over the lower pin. Gently lay the gel down over the REP Prep making sure no bubbles remain under the gel.
  - f. Place the top half of the Gel Cassette over the gel. Make sure the 2D barcode is located in the upper right corner of the cassette.

- g. Place a Positive ID Barcode Label on the upper right hand side of the gel backing. Select the barcode that starts with the letter "G".

F. Close the main door of the instrument.

### III. Automated Gel Electrophoresis

- A. Click the Start button on the menu bar. Select the **Serum Immunofixation (IFE) 15 (Acid Violet)** or **Urine Immunofixation (IFE) 15 (Acid Violet)** test name from the drop down menu. Ensure the toggles for all Run Processes are set to "Yes" and click the Start Run button. The analyzer will load samples when appropriate, apply samples, electrophorese, immunofix, wash, stain, destain, dry and scan the gel. For details of Automated Gel Electrophoresis parameters, contact Technical Services.
- B. After scanning, the Gel Cassette with the finished gel will be located in the scanner port of the front side of the instrument. If gel storage is required, remove and discard the two gel blocks.
- C. After every test: discard the used blotters, Applicator Blades, Stain Cups and sample cups as biohazardous waste. Clean any residual stain from the electrophoresis platen, Gel Cassette and the Reagent Roller bar. For daily, weekly, and monthly maintenance reference the SPIFE Nexus Operator's Manual.

**Qualitative Evaluation:** The SPIFE IFE-15 Gel will be automatically scanned. Refer to the QuickScan Touch Plus Operator's Manual for scanning parameters.

**Quality Control:** It is recommended that each reagent lot is evaluated with a known patient(s) or IFE controls such as Cat. No. 9400 ImmunoFix Controls. Follow federal, state, and local guidelines for quality control.

**Stability of End Product:** The completed, stained and dried immunofixation gel is stable for an indefinite period of time.

### INTERPRETATION OF RESULTS

**Normal sample:** No monoclonal present, immunofixation lanes have faint diffused stain or blush of color or variable intensity that reflects the normal distribution of immunoglobins.

**Polyclonal:** No monoclonal present, a diffuse increase in at least one heavy chain and both light chains.

**Monoclonal:** A monoclonal protein is characterized by a well-defined restricted band in a heavy chain lane with a corresponding band in a light chain lane. The monoclonal protein band on the immunofixation pattern will occupy the same migration position and shape as the monoclonal band on the reference protein electrophoresis pattern. The abnormal protein is identified by the corresponding antiserum used. Because of the increased sensitivity of the procedure, it is not uncommon to see a fixed band that is not visible in the serum protein procedure. The majority of monoclonal proteins migrate in the cathodic (gamma) region of the protein pattern. However, due to their abnormality, they may migrate anywhere within the protein electrophoresis pattern.

When low concentrations of M-protein are present, the immunofixation band may appear on the stained background of the polyclonal immunoglobulin. A stained background may also appear when the M-protein is present along with a large polyclonal increase.

#### Other:

Reaction with light chain antisera only could indicate either a free light chain gammopathy or (rarely) IgD or IgE gammopathy. (See Further Testing)

Reaction with heavy chain antisera may indicate (rarely) heavy chain disease or an atypical light chain.<sup>3</sup>

**Multiple M- Proteins:** On rare occasion biclonal (two M-proteins) or oligoclonal (more than two) patterns may occur.

**Fc fragments** - Proteolysis of the immunoglobulin into Fac and Fc fragments may occur either in vivo or in vitro. The Fc fragments may maintain antigen antibody specificity to a heavy chain only, usually migrate in the alpha-2 area, and appear monoclonal in nature, with no corresponding

band in the light chain lane. Fab fragments react with heavy and light chain antisera and are polyclonal in appearance.<sup>4</sup>

**Restricted heterogeneity/Ladder light chains<sup>5</sup>** - A pattern of multiple regularly spaced restricted bands reacting with light chain antisera may be seen in urine with a high concentration of polyclonal light chains.<sup>6</sup>

**Cathodal bands** - An extremely cathodal band present in the SP lane that does not react with antisera is consistent with lysozyme. Elevated lysozyme may be seen in monocytic and monomyelocyte leukemias.<sup>7</sup>

For an in-depth discussion of IFE interpretation, call Helena Laboratories toll free and request the free publication "An Immunofixation Tutorial" Book F.

#### Further Testing Required

Specimens containing a band on serum protein electrophoresis suggestive of a monoclonal protein, but which do not react with IgG, IgA or IgM antisera, may require further testing as follows:

1. Serum samples which have a precipitin band with Kappa or Lambda Light Chain Antisera but no band corresponding with IgG, IgA or IgM antisera may have a free light chain or they may have an IgD or IgE monoclonal protein. Such samples should be tested with ImmunoFix IgD and IgE antisera.
2. A CRP band may be detected in patients with acute inflammatory response.<sup>8</sup> CRP appears as a narrow band on the most cathodic end of the high resolution agarose protein electrophoresis pattern. Evaluated Alpha-1 Antitrypsin and haptoglobin (acute phase proteins) are supportive evidence for the presence of a CRP band. Patients with a CRP band will have a positive CRP by latex agglutination or an elevated quantitative CRP.

#### LIMITATIONS

1. Antigen excess will occur if there is not a slight antibody excess or antigen/antibody equivalency at the site of precipitation. Antigen excess in IFE is usually due to a very high level of immunoglobulin in the patient sample. The dissolution of immunoprecipitation is manifested by a loss of protein at the point of highest antigen concentration, resulting in staining at the margins of the band, while leaving the central area with little demonstrable protein stain. In this case, it may be necessary to adjust the protein content of the sample by dilution. Electrophoresing excessive amounts of antigen decreases resolution and requires higher concentrations of antibody. For optimum separation and sufficient intensity for visual detection, care must be taken in adjusting antibody content, sample concentration, time and voltage.
2. Monoclonal proteins may occasionally adhere to the gel matrix, especially cryoglobulins or IgM. These bands will appear in all five antisera reaction areas of the gel. However, where the band reacts with the specific antisera for its heavy chain and light chain, there will be a marked increase in size and staining activity, allowing the band to be identified.
3. An application artifact may appear as a fine clear line (negative space) that may be visible to a faint degree across the entire gel in the beta region. This can on occasion cause the edge of a normal blush to appear slightly blunted.
4. Therapeutic monoclonal antibodies may be used in the treatment of multiple myeloma as well as various other malignancies or medical conditions. If present in sufficient concentration, a humanized therapeutic monoclonal antibody will react with antisera in a manner comparable to a pathologic monoclonal protein.<sup>3,9</sup>
5. Light chains associated with IgA or IgD heavy chains may on rare occasion be difficult to visualize. The structure of some IgA dimers may potentially block the light chain epitopes, decreasing the antisera reaction. This occurs more commonly with lambda than kappa.<sup>5,10</sup>

6. It is possible that not all monoclonal proteins are detected by immunofixation. Not all clinically significant monoclonal gammopathies will display a distinct band detectable by serum protein electrophoresis.<sup>11</sup>

#### PERFORMANCE CHARACTERISTICS

Serum and urine samples containing IgG, IgA, IgM, Kappa light chain and Lambda light chain monoclonal proteins were tested using the SPIFE Touch and SPIFE Nexus instruments. The test results showed complete concordance between instruments.

#### SENSITIVITY

A pathological serum sample with a monoclonal protein was serially diluted and the dilutions electrophoresed on the SPIFE IFE gels on the SPIFE Nexus. After visual inspection of the gel, the lowest detectable concentration of a monoclonal protein was between approximately 0.01 and 0.02 g/L (1 and 2 mg/dL).

Serial dilutions of a pathological urine sample containing a monoclonal were analyzed on the SPIFE Nexus using blade application on the SPIFE IFE gels. The sensitivity was determined to be approximately 0.01 g/L (1 mg/dL) for a single band when using three blade applications of neat urine.

#### BIBLIOGRAPHY

1. Cawley, L.P., Minard, B.J., Tourtellotte, W.W., Ma, B.I., & Chelle, C. Immunofixation electrophoretic techniques applied to identification of proteins in serum and cerebrospinal fluid. *Clin Chem.* 1976; 22(8): 1262-1268.
2. Ritchie RF, Smith R. Immunofixation. III. Application to the study of monoclonal proteins. *Clin Chem.* 1976; 22(12):1982-1985.
3. Keren DF. Therapeutic complications: A caveat for M-protein detection. *The Journal of Applied Laboratory Medicine.* 2016; 1(4):342-345.
4. Keren DF. In: *Protein Electrophoresis in Clinical Diagnosis*. American Society for Clinical Pathology Press; 2012:125-134.
5. Yu M, Bruns DE, Katzmann JA, Silverman LM, Murray DL. Restricted IGG-kappa and free alpha-heavy-chain bands in an asymptomatic 62-year-old man. *Clin Chem.* 2018; 64(2):265-268.
6. Macnamara EM, et al. *Clin Chem.* 1991; 37(9): 1570-1574.
7. Ritzmann SE, editor. *Protein Abnormalities Volume 3. Proteins in Bodily Fluids, Amino Acids, and Tumor Markers: Diagnostic and Clinical Aspects*. New York (NY): Allen R Liss; 1983; 130.
8. Jeppson JO, Laurell CB, Franzén B. Agarose gel electrophoresis. *Clin Chem.* 1979; 25(4):629-638.
9. McCudden CR, Jacobs JFM, Keren D, Cailion H, Dejoie T, Andersen K. Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences. *Clin Biochem.* 2018; 51:72-79.
10. Hashimoto N, Chandor S, Mandy W, Yokoyama M. Atypical IgA with hidden light chain. *Clin Exp Immunol.* 1970; 6(6):941-949.
11. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clinic Proceedings.* 2003; 78(1):21-33.

For Sales, Technical and Order Information and Service Assistance, call 800-231-5663 toll free.

Helena Laboratories warrants its products to meet our published specifications and to be free from defects in materials and workmanship. Helena's liability under this contract or otherwise shall be limited to replacement or refund of any amount not to exceed the purchase price attributable to the goods as to which such claim is made. These alternatives shall be buyer's exclusive remedies. In no case will Helena Laboratories be liable for consequential damages even if Helena has been advised as to the possibility of such damages.

The foregoing warranties are in lieu of all warranties expressed or implied including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose.

© 2023-2026 Helena Laboratories, Corp.

Shaded areas indicate that the text has been modified, added or deleted.



1530 Lindbergh Dr.  
Beaumont, Texas 77707 USA

Pro. 271  
5/26(9)